A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis (NCT06028438), a randomized phase 2 study. The primary outcome is Change From Baseline in Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) at Week 12.

2. Clinical Question

3. Trial Design

This was a Phase 2a, randomized, double-blind, parallel-group, proof-of-concept study. It evaluated nipocalimab and certolizumab combination therapy in participants with active rheumatoid arthritis despite prior treatment with advanced therapies. The registry record lists an enrollment of 103 and a completed status. The study start is listed as 2023-08-15, and primary completion as 2024-08-29.

Participants were assigned to one of two groups: certolizumab with IV placebo, or certolizumab with IV nipocalimab. Both groups received certolizumab subcutaneously. The arm descriptions give initial visits at Week 0, 2, and 4, followed by the stated Week 6 to 22 schedule. The registry record does not report the allocation ratio or the procedures used to generate and conceal the random assignment.

The primary outcome was change from baseline in DAS28-CRP at Week 12. The posted primary analysis population was the full analysis set, defined as all randomized participants who received at least one partial or complete dose of any study intervention. The primary analysis used an ANCOVA comparison of least-squares means. The record lists eight secondary outcomes, including ACR response measures, DAS28-CRP remission and low disease activity, and changes in HAQ-DI and CDAI.

Although the study is marked completed, details such as the actual masking procedures, treatment adherence, participant flow, and reasons for any discontinuations are not reported in the registry record. The record also does not report a sample-size justification for the trial’s design. The planning illustrations associated with observed secondary effects are not evidence of the trial’s original design target.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: The full analysis set (FAS) included all randomized participants who received at least 1 dose (partial or complete) of any study intervention.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Change From Baseline in Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) at Week 12, measured over Baseline (Week 0), Week 12.

The primary endpoint was change from baseline in DAS28-CRP at Week 12. DAS28 is a composite measure of rheumatoid arthritis disease activity. It uses tender and swollen joint counts from 28 evaluated joints, the participant’s global assessment of disease activity, and C-reactive protein. The described joint set includes shoulders, elbows, wrists, finger joints, and knees on both sides of the body.

The endpoint is reported on a scale from 0 to 10, with higher scores indicating more disease activity. The registry record defines negative change from baseline as improvement. Using a composite measure allows the analysis to represent several aspects of disease activity together rather than relying on a single joint count or laboratory measure. This is a general reason composite endpoints may be used; the registry record does not state why this particular endpoint was selected over the other listed measures.

The reported arm results are least-squares mean changes, with 95% confidence intervals. The certolizumab-plus-placebo group had a reported change of -1.86, with a 95% confidence interval from -2.55 to -1.17. The combination group had a reported change of -1.92, with a 95% confidence interval from -2.59 to -1.25. The adjusted comparison, rather than either arm’s change considered alone, addresses the trial’s primary question. The registry record does not report a threshold for interpreting the clinical importance of a difference in this endpoint.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The primary outcome is continuous: it records change in a numeric disease activity score rather than simply whether a participant did or did not meet a response definition. The registry reports least-squares means for each group and a least-squares mean difference from an ANCOVA. Least-squares means are model-based group estimates. ANCOVA is a general approach for comparing groups while accounting for specified covariates. Which covariates were included, how they were coded, and how model assumptions were assessed are not reported in the registry record.

What does the confidence interval add?

A point estimate gives one summary of the observed comparison; a confidence interval communicates its statistical uncertainty. In repeated use of a procedure under its assumptions, confidence intervals at the stated level would cover the true parameter at that level over the long run. A particular interval is not a probability statement about where the true value lies. For this primary comparison, the 95% confidence interval runs from -0.60 to 0.48 around the estimated difference of -0.06. Its inclusion of zero means the result does not clearly distinguish a difference from no difference. Its width also matters: plausible values include differences in either direction, so the estimate should not be treated as a precise finding of equality.

How should the p-value be read?

The p-value is 0.822 for the sponsor-reported primary comparison. In general, a p-value measures how incompatible the observed data are with a specified null model, assuming the model and analysis are appropriate. It is not the probability that the null hypothesis is true, a measure of clinical importance, or a measure of the probability that the result is due to chance. It should be interpreted alongside the effect estimate and confidence interval, not on its own. The registry record does not report whether the analysis was one- or two-sided, beyond the analysis details posted with the result.

Why distinguish within-group change from a group comparison?

Each arm’s least-squares mean change describes change from baseline in that group. Those changes are not the same as the randomized comparison. Participants may change over time in both groups, and the causal question represented by the trial is the contrast between assigned groups. The ANCOVA least-squares mean difference is the reported comparison for that question. The registry record’s endpoint description states that negative changes indicate improvement, but that does not make the difference between two negative within-group values a standalone test of the treatment contrast.

What do the secondary planning illustrations mean?

General power calculations estimate how many participants might be needed to detect a specified effect under stated assumptions. The posted illustrations use observed secondary endpoint effects and state assumptions of a two-sided significance level of 0.05, equal allocation, and a normal approximation. They consider planning for 100%, 75%, and 50% of the observed effect. These are planning illustrations, not observed power and not the trial’s original sample-size justification. Calculations based on an effect observed in a small study can be unstable, particularly when that estimate is uncertain. The registry record does not report the trial’s own sample-size rationale.

For binary endpoints, a risk difference is a contrast between the proportions meeting a response definition in the two groups. An interval for that contrast describes uncertainty in the estimated difference. In general, when such an interval spans zero, the data do not clearly resolve whether the response proportion is higher in one group or the other. The secondary outcomes also include response categories and other disease activity measures. Their results should be considered exploratory unless the analysis plan and multiplicity approach support stronger confirmatory interpretation.

Why do over-dispersion and model fit matter generally?

Over-dispersion is a general concern when observed variation is greater than a statistical model expects. If a model understates variability, standard errors may be too small and confidence intervals too narrow. This concept is relevant to statistical modeling broadly, but the posted primary analysis is ANCOVA for a continuous endpoint, and the registry record does not report an over-dispersion assessment or a model-fit evaluation. It would therefore be inappropriate to claim that over-dispersion was present or addressed in this trial.

Interpretation also depends on the population analyzed, missing outcome handling, and prespecified analysis decisions. The full analysis set is defined in the record, but the record does not describe imputation, the handling of missing Week 12 measurements, or sensitivity analyses. It also does not report an analysis plan that would clarify whether the primary model and secondary comparisons were specified before outcomes were examined.

10. Analyses Reported by the Sponsor

The registry reports the sponsor’s primary comparison as an ANCOVA estimate: the least-squares mean difference was -0.06, with a 95% confidence interval from -0.60 to 0.48 and p =0.822. This is the reported adjusted analysis and is the principal inferential result for the primary endpoint. The posted arm-level least-squares mean changes provide context, but they do not replace the adjusted between-group comparison.

The registry record does not report a separate recalculated primary comparison. The unadjusted recalculations available for secondary binary outcomes are distinct from the sponsor’s primary ANCOVA and should not be substituted for it. Unadjusted calculations may use only posted summary statistics and may not reproduce the sponsor’s analysis population, covariate adjustment, or other analytic choices. The registry record does not report the full ANCOVA model specification, so the exact role of each modeling decision cannot be assessed from the posted result alone.

No discrepancy between the sponsor’s reported primary analysis and a recalculation is identified in the registry record. Accordingly, the sponsor-reported ANCOVA estimate is the relevant posted primary result. Its confidence interval and p-value support a cautious reading: the estimate is close to zero, but the interval remains compatible with differences in either direction. The registry record does not report enough detail to independently reproduce the sponsor’s adjusted analysis.

11. Multiplicity, Missing Data and Analysis Populations

The record lists one primary endpoint and eight secondary outcomes. The primary endpoint is change from baseline in DAS28-CRP at Week 12. The secondary outcomes include several ACR response categories, DAS28-CRP remission and low disease activity, and changes in HAQ-DI and CDAI. The registry record does not report a prespecified multiplicity strategy, such as an adjustment procedure or an ordered testing plan. Without that information, it is not possible to determine whether the secondary results were intended to support confirmatory claims or how any family of statistical tests was controlled.

Unadjusted secondary p-values, where available from recalculation, do not account for testing multiple outcomes. In general, conducting many tests increases the chance of at least one result appearing notable even when there is no underlying difference. That does not mean every secondary result is false; it means the strength of evidence is harder to judge without the analysis plan and multiplicity approach. The sponsor’s primary result remains the central comparison, while secondary patterns are best interpreted cautiously.

The full analysis set is defined as all randomized participants who received at least one partial or complete dose of any study intervention. The record does not report how many randomized participants were excluded from that set, whether all included participants had Week 12 measurements, or how missing measurements were handled. It also does not report imputation methods, sensitivity analyses, or assumptions about missing outcomes. These omissions limit assessment of whether missing data could have affected the estimates.

The registry record does not report interim analyses, stopping rules, or whether the primary analysis population and methods were finalized before results were examined. Those details should not be inferred. The posted definition of the full analysis set and the reported ANCOVA identify some aspects of the analysis, but they do not establish all features of a protocol or statistical analysis plan.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: myocardial infarction (3.2%), soft tissue infection (2.4%), cellulitis (1.6%), influenza (1.6%), pneumonia (1.6%).

The registry reports serious adverse events in 1 of 41 participants in the certolizumab-plus-placebo group and 7 of 62 participants in the certolizumab-plus-nipocalimab group. Other adverse events were reported for 7 of 41 and 23 of 62 participants, respectively. No deaths were reported in either group. These are counts within the groups at risk, not adjusted comparisons, and the registry record does not provide a statistical analysis of these safety differences.

The serious-event terms listed include myocardial infarction, soft tissue infection, cellulitis, influenza, pneumonia, and pneumonia respiratory syncytial viral, with the posted percentages ranging from 1.6% to 3.2%. The record does not specify in that listing how each term is distributed by treatment group, so group assignment should not be inferred from the terms and percentages alone.

Safety counts describe events reported during the study; they do not establish that a treatment caused an event or that an observed difference is reliable. Interpretation is limited by the number of participants and by the absence of fuller information about event timing, exposure, severity, follow-up, and statistical comparisons. These registry figures should be read as descriptive safety reporting rather than a definitive assessment of comparative safety.

13. What the Result Does, and Does Not, Mean

The primary result is an estimated difference in Week 12 change in DAS28-CRP between two randomized groups: certolizumab with nipocalimab and certolizumab with placebo. The posted ANCOVA estimate was -0.06, with a 95% confidence interval from -0.60 to 0.48 and p =0.822. The estimate is near zero, but the interval includes values on both sides of zero. This means the posted result does not establish a clear difference between the groups, and it also does not establish that they are equivalent.

The result is specific to this Phase 2a trial, its enrolled population, its treatment schedules, its analysis population, and its Week 12 endpoint. It does not establish what would occur in other groups of people, under different schedules, or over longer follow-up. The registry record does not report a clinically important difference threshold, so the statistical estimate cannot be translated into a judgment about whether a particular difference would matter to participants.

The secondary outcomes add descriptive context but do not resolve the primary uncertainty. Their results span different endpoint definitions, and the registry record does not report a multiplicity approach for interpreting them together. Planning illustrations based on observed effects are not evidence that the trial had a particular probability of detecting an effect.

Safety counts are also descriptive. The recorded serious events, other adverse events, and absence of deaths in both groups should not be used alone to infer causation or to make a broad comparative safety conclusion. Overall, the registry record documents an estimated primary comparison with substantial uncertainty and does not supply enough detail to draw stronger conclusions about clinical importance, equivalence, or outcomes beyond those posted.

14. Why This Trial Matters Statistically

This trial raises a useful statistical question about interpreting a randomized comparison when the estimated group difference is small relative to its uncertainty. The primary estimate of -0.06 is close to zero, but the 95% confidence interval extends from -0.60 to 0.48. Reading both the estimate and interval avoids treating a nonsignificant result as proof that the groups are identical. It also keeps attention on what range of differences the posted analysis remains compatible with.

The design compares the addition of nipocalimab with IV placebo while both groups receive certolizumab. That active comparator structure focuses the primary contrast on the combination strategy versus certolizumab with placebo, rather than on either group’s change considered in isolation. The ANCOVA result is therefore more informative for the stated comparison than arm-level changes alone.

The record also illustrates why an endpoint portfolio needs a clear analysis plan. A primary continuous measure is accompanied by multiple secondary outcomes with different definitions. In general, multiplicity and missing-data decisions affect how confidently a collection of results can be interpreted. The registry record does not report those decisions in enough detail to assess their role, making restraint especially important when reading secondary patterns.

Finally, observed-effect planning illustrations are not a substitute for the trial’s original sample-size rationale. Using an effect observed in the same study to illustrate possible future planning can be informative, but it does not reveal the study’s prespecified design assumptions or its achieved power. Distinguishing these uses of statistical calculations helps prevent exploratory estimates from being mistaken for design evidence or definitive conclusions.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary between-group interval spans values on either side of zero, so the estimate does not sharply identify the direction or size of a difference. The registry record does not report a clinically important difference threshold, limiting interpretation of the interval in terms of clinical relevance. The reported arm sizes were 41 and 62, and the total enrollment was 103; the record does not provide fuller participant-flow information to clarify how enrollment relates to the analyzed population.

Important analysis details are not reported in the registry record, including the ANCOVA covariates, model diagnostics, missing-data methods, sensitivity analyses, and any prespecified multiplicity strategy. The record defines the full analysis set but does not state how many participants lacked Week 12 outcomes or how such data were handled. These gaps limit independent assessment of robustness.

The posted secondary outcomes cover multiple measures, but sponsor analyses for them are not listed. Unadjusted calculations based on posted summaries cannot necessarily reproduce an analysis using participant-level data or the sponsor’s methods. The record also does not report the trial’s sample-size justification, interim analyses, or stopping rules. Planning illustrations based on observed secondary effects should not be read as the original design rationale or as observed power.

Safety information is presented descriptively, without reported comparative statistical analyses or fuller details about event timing and exposure. The serious-event term percentages are not assigned to groups in the listed information. Consequently, these figures cannot establish a causal interpretation or a precise comparative safety profile. The study’s Phase 2a scope and Week 12 primary assessment also limit conclusions to the reported trial setting and time point.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis — NCT06028438.
• Registry record last updated 2025-10-16; status last verified 2025-09.
• Results first posted 2025-10-16.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

This completed Phase 2a randomized, double-blind, parallel-group study enrolled 103 participants with active rheumatoid arthritis despite prior advanced therapy. It compared certolizumab plus IV nipocalimab with certolizumab plus IV placebo. The primary endpoint was change from baseline in DAS28-CRP at Week 12, analyzed using ANCOVA in a full analysis set defined by randomization and receipt of at least one partial or complete study-intervention dose.

The sponsor-reported least-squares mean difference was -0.06, with a 95% confidence interval from -0.60 to 0.48 and p =0.822. The estimate is close to zero, but the interval allows differences in either direction. Secondary outcomes covered ACR responses, DAS28-CRP states, HAQ-DI, and CDAI. The registry record does not report multiplicity or missing-data methods, the original sample-size rationale, or a clinical-importance threshold. Safety events are reported descriptively.